News und Analysen
Tilray festigt seine weltweite Führungsposition bei medizinischem Cannabis durch eine erhebliche Steigerung der Produktion, um der internationalen Nachfrage gerecht zu werden
Der erweiterte Anbau in Quebec und Portugal stärkt die globale Cannabis-Plattform von Tilray und erhöht die jährliche Gesamtproduktionskapazität auf rund 275 Tonnen, um der steigenden
Viking Stock Fell After Earnings, But the Numbers Tell a Different Story
Key Points
- Interested in Viking Holdings Ltd.? Here are five stocks we like better.
- Viking Holdings delivered another strong quarter, with revenue, EBITDA and earnings all improving year over
Baytex Energy Eyes Duvernay Growth After Eagle Ford Sale, Ramps Up Buybacks
Key Points
- Interested in Baytex Energy Corp? Here are five stocks we like better.
- Baytex is refocusing on Canada after selling its Eagle Ford assets, simplifying operations and strengthening its
Valneva Aktie: EMA validiert PF-07307405, Nettoverlust 63,3 Millionen
Valneva hat einen ereignisreichen Monat hinter sich. Die Aktie legte in der vergangenen Woche…
Der Beitrag Valneva Aktie: EMA validiert PF-07307405, Nettoverlust 63,3 Millionen erschien zuerst auf k
Viking Q2 Earnings Call Highlights
Key Points
- Interested in Viking Holdings Ltd.? Here are five stocks we like better.
- Strong second-quarter results: Revenue rose 16.5% year over year to $2.2 billion, adjusted EBITDA increased
Orbiting Wealth: Institutions Load Up SpaceX
Key Points
- Interested in SpaceX? Here are five stocks we like better.
- Major institutions, including Harvard, the University of California, Google and Founders Fund, have disclosed sizable SpaceX
EQS-News: FamiCord AG wechselt mit Wirkung zum 19. August 2026 ins Scale Segment
EQS-News: FamiCord AG wechselt mit Wirkung zum 19. August 2026 ins Scale Segment
Oncocyte Eyes Faster, Less Invasive Heart Transplant Rejection Testing
Key Points
- Interested in Oncocyte Corp? Here are five stocks we like better.
- Insight Molecular Diagnostics is pursuing heart-transplant applications for its GraftAssureDx donor-derived cell-free
Intellia: 106,6-Millionen-Dollar-Verlust im Q2
Intellia Therapeutics fokussiert sich nach dem Abschluss des zweiten Quartals 2026 auf die klinische…
Der Beitrag Intellia: 106,6-Millionen-Dollar-Verlust im Q2 erschien zuerst auf kapitalmarktexper
Valneva nach EMA-Validierung: Wie tragfähig ist die Neubewertung?
Ausgangslage Valneva hat einen turbulenten Handelstag hinter sich: Die Aktie schoss am Freitag um…
Der Beitrag Valneva nach EMA-Validierung: Wie tragfähig ist die Neubewertung? erschien zuerst auf k
PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity
Key Points
- Interested in Pacific Biosciences of California, Inc.? Here are five stocks we like better.
- PacBio lowered its revenue outlook as customers transition more slowly than expected to
Natera Spotlights Record Signatera Volumes, Raises Outlook at Canaccord Conference
Key Points
- Interested in Natera, Inc.? Here are five stocks we like better.
- Natera raised its outlook after broad-based second-quarter momentum, including record Signatera volumes, strong
Stratec Q2 Earnings Call Highlights
Key Points
- Interested in Stratec SE? Here are five stocks we like better.
- Stratec maintained its 2026 guidance for medium- to high-single-digit constant-currency revenue growth and an adjusted
KinderCare Learning Companies Q2 Earnings Call Highlights
Key Points
- Interested in KinderCare Learning Companies, Inc.? Here are five stocks we like better.
- Second-quarter results weakened: Revenue fell slightly to $698 million, while the company
EQS-News: STRATEC MIT ERGEBNISSEN FÜR DAS ERSTE HALBJAHR 2026
EQS-News: STRATEC MIT ERGEBNISSEN FÜR DAS ERSTE HALBJAHR 2026
Sensus Healthcare Q2 Earnings Call Highlights
Key Points
- Interested in Sensus Healthcare, Inc.? Here are five stocks we like better.
- Second-quarter revenue fell sharply to $2.3 million from $7.3 million a year earlier, primarily because
Merlin, Inc. Common Stock Q2 Earnings Call Highlights
Key Points
- Interested in Merlin, Inc. Common Stock? Here are five stocks we like better.
- Second-quarter revenue rose to approximately $2.2 million, up $1.2 million sequentially, while Merlin
Heartflow Q2 Earnings Call Highlights
Key Points
- Interested in Heartflow, Inc.? Here are five stocks we like better.
- Strong second-quarter growth: Revenue rose 48% year over year to $64.1 million, while global case volume increased
Capricor Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Capricor Therapeutics, Inc.? Here are five stocks we like better.
- FDA review remains ongoing: Capricor plans to amend deramiocel’s application to pursue an upper-limb
Valneva Q2 Earnings Call Highlights
Key Points
- Interested in Valneva SE Sponsored ADR? Here are five stocks we like better.
- First-half performance weakened: Revenue fell to €65.8 million from €97.6 million, while the operating
MediWound Q2 Earnings Call Highlights
Key Points
- Interested in MediWound Ltd.? Here are five stocks we like better.
- EscharEx development advanced: MediWound is enrolling its global Phase III VALUE trial, targeting completion and
CorMedix Q2 Earnings Call Highlights
Key Points
- Interested in CorMedix Inc? Here are five stocks we like better.
- CorMedix reported strong second-quarter results with revenue of $101.9 million, adjusted EBITDA of $58.7 million and
Cellebrite DI Q2 Earnings Call Highlights
Key Points
- Interested in Cellebrite DI Ltd.? Here are five stocks we like better.
- Cellebrite lowered its 2026 outlook after second-quarter ARR reached $508 million, below guidance, as large
Entain H1 Earnings Call Highlights
Key Points
- Interested in Entain Plc? Here are five stocks we like better.
- Entain reported strong first-half growth: Online net gaming revenue increased 7% in constant currency, group EBITDA
EQS-News: Eckert & Ziegler im ersten Halbjahr 2026 auf Kurs
EQS-News: Eckert & Ziegler im ersten Halbjahr 2026 auf Kurs